linjc16/ctgov huggingface dataset:
The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care

Study Overview
=================
Brief Summary
-----------------
Cardiogenic shock is a frequent reason for hospitalization in critical care units, with high mortality (50%). Several French registries have been created to improve knowledge of the prognostic factors of cardiogenic shock. In recent years, temporary mechanical circulatory support has become more important in cardiogenic shock. The monitoring of catecholamines is also performed with a global score: the vaso-inotropic score. The purpose of our study is to consider using these new data and techniques to create a cohort of cardiogenic shock within our critical care unit. This observational study is based on clinical, biological, and hemodynamic data recorded during the ICU stay of patients for cardiogenic shock. The primary endpoint is the relationship between the hemodynamic evolution of cardiogenic shock and in-hospital mortality.

Official Title
-----------------
The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care

Conditions
-----------------
Cardiogenic Shock

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized in ICU for cardiogenic shock Patient with cardiogenic shock as defined by the FRENSCHOCK2 study criteria Exclusion Criteria: Patient with cardiogenic shock in the context of septic shock and hemorrhagic shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of in-hospital mortality after cardiogenic shock |  | 5 years | 
| Vaso-inotropic score after cardiogenic shock | vasoactive-inotropic score (VIS) Maximal VIS (VISmax) is calculated using the highest doses of vasoactive and inotropic medications administered. VISmax categories: 0-5, >5-15, >15-30, >30-45, and >45 points. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiogenic Shock, vaso-inotropic score
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Study Overview
=================
Brief Summary
-----------------
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Detailed Description
-----------------
Some studies have shown the potential of ctDNA in renal cancer monitoring, but the amount of ctDNA released in renal cancer is the lowest among non-cranial tumors. Even in advanced patients, the detection rate of tumor system mutation is less than 50%. DNA methylation is important in the process of tumor occurrence and development. However, no studies have focused on the value of ctDNA methylation in monitoring renal cancer, nor have large prospective cohort studies been conducted in patients with renal cancer. This study intended to analyze the dynamic changes of circulating tumor DNA and its methylation status in patients with kidney cancer from preoperative to long-term follow-up, and to compare the evaluation value of methylation detection with traditional imaging examination and traditional blood tumor markers in the monitoring process.

Official Title
-----------------
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Conditions
-----------------
Carcinoma, Renal Cell Carcinoma, RCC, Kidney Neoplasms, Kidney Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed renal cell carcinoma Without any treatment Agree and accept radical surgical treatment Signed written informed consent ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1 Follow up protocol and related procedures Exclusion Criteria: Had other cancers Had received any antitumor therapy before Known or suspected active autoimmune disease Informed consent is not possible due to medical or psychiatric problems Have clinical symptoms or diseases of the heart that are not well controlled Patients judged by the investigators to be unsuitable for inclusion in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To explore the predictive effect of ctDNA methylomics on the prognosis and medication guidance of renal carcinoma. |  | 5 years | 
| To explore the advance time of ctDNA methylomics in monitoring postoperative recurrence of renal cancer compared with imaging. |  | 5 years | 
| The molecular mechanism of renal cancer recurrence was analyzed with baseline tissue and circulating methylation profiles. |  | 5 years | 
| A renal cancer recurrence risk model was established based on clinical information, molecular risk factors and ctDNA methylomics |  | 5 years |
Comparison of Patient-controlled Analgesia Regimenfor Postoperative Pain in Patients Undergoing Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
Patients who undergoing total knee arthroplasty under spinal analgesia will be recruited and randomly assigned to the following two groups according to the regimen of PCA: (A) opioid group who receive only fentanyl citrate 1200mcg for continuous infusion drug, (B) non-opioid group who receive ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug. All the patients will receive additional fentanyl citrate as bolus injection drug if they need more analgesics postoperatively.

Official Title
-----------------
Comparison of Patient-controlled Analgesia With Background Opioid Versus Non-opioid Infusion for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty: a Randomized, Non-inferiority Study

Conditions
-----------------
Postoperative Pain, Acute

Intervention / Treatment
-----------------
* Drug: Fentanyl
* Drug: ketorolac tromethamine with nefopam hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status I-II undergoing elective total knee arthroplasty under spinal anesthesia Exclusion Criteria: history of stomack ulceration increased ICP bronchial asthma allergy on aspirin, NSAIDs, Nefopam drug user of antiplatelet or anticoagulant

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: opioid group<br>IV-PCA consisted of fentanyl | Drug: Fentanyl<br>* opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug<br>* Other names: opioid group;|
| Active Comparator: non-opioid group<br>IV-PCA consisted of ketorolac and nefopam | Drug: ketorolac tromethamine with nefopam hydrochloride<br>* non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain score | evaluated by visual analogue scale (VAS) | 24 hours after the surgery |
Study of the Reduction of the Prescriptions of Benzodiazepines and Related

Study Overview
=================
Brief Summary
-----------------
The significant consumption of Benzodiazepines and related drugs in the elderly outside of good practice recommendations is a major issue in the care of the elderly. Adverse effects have been the subject of numerous studies, leading to falls, addictions and even deaths. The general practitioner is often faced with long-term medication intake which is not consistent with a good benefit/risk balance, but stopping or reducing the dosage remains a problem in current practice. The Aftercare and Geriatric Rehabilitation services due to their operation (several weeks of hospitalization) seek to adapt the patient's therapies in order to obtain the most convincing benefit/risk balance possible. A reduction or withdrawal of treatments with Benzodiazepines or related drugs are therefore frequently initiated.

Detailed Description
-----------------
The aim of this research is to quantify among the patients who benefited from a dosage reduction of Benzodiazepines and related drugs during a stay in the Geriatric Care and Aftercare and Rehabilitation department, the number of patients who had an increase of this treatment within 12 weeks following discharge from hospitalization.

Official Title
-----------------
Study of the Reduction of the Prescriptions of Benzodiazepines and Related After the Discharge of a Service of Follow-up Care and Geriatric Rehabilitation

Conditions
-----------------
Depression in Old Age

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject (≥ 75 years old) Subject discharged from a geriatric Follow-up Care and Rehabilitation service for whom a reduction in the dosage of Benzodiazepines and related drugs was carried out during hospitalization and who returned home (individual or EHPAD) after hospitalization. Subject not opposing, after information, the reuse of their data for the purposes of this research. Exclusion Criteria: Subject having expressed opposition to participating in the study. Subject having treatment with Benzodiazepine to prevent recurrence of epileptic seizures.

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patients who had an increase in Benzodiazepines in the 12 weeks following discharge from hospitalization. |  | 12 weeks following discharge from hospitalization. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression in Old Age, Benzodiazepines drugs, Geriatrics
Antidiabetic Potiential of Moringa and Dom Extract

Study Overview
=================
Brief Summary
-----------------
The Antidiabetic potential of Hyphaene thebaica fruits and Moringa oleifera leaves will be investigated in diabetic patients (type 2). The patients will be maintained on tea of both drugs for 6 weeks. The fasting blood glucose levels of patients will be checked on a daily basis. Other blood biomarkers will be also reported such as insulin concentration, Lipid profile, liver enzymes, c-peptide and glycated hemoglobin

Official Title
-----------------
Antidiabetic Potential of Hyphanea Thebaica Fruits and Moringa Olifera Leaves

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: MorDom


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetic patients type 2 Exclusion Criteria: liver failure heart failure renal failure

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental group<br> | Dietary Supplement: MorDom<br>* oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)<br>|
| No Intervention: Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood glucose level | measured by fast blood test | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood level of lipid profile | Blood samples were drawn to measure levels of LDL, HDL, triglycerides, total cholesterol | two weeks | 
| Liver enzymes | Blood samples were drawn to measure levels of ALT and AST | two weeks | 
| C-peptide level | Blood samples were drawn to measure fasting and postprandial levels of c-peptide | two weeks | 
| Insulin level | Blood samples were drawn to measure fasting and postprandial levels of insulin | two weeks |
Serum Ferritin In CKD Patients Serum Ferritin

Study Overview
=================
Brief Summary
-----------------
Variability of serum ferritin in CKD patients and how these variables may affect the treatment decisions with iron supplements

Detailed Description
-----------------
Serum ferritin has a wide range Variability in CKD patients this makes the use of serum ferritin as an indicator of iron deficiency is limited and mostly CKD is secondary to inflammation so serum ferritin as ferritin is an acute phase reactants so it will be very high in CKD patients ,

Official Title
-----------------
Variability of Serum Ferritin in CKD Patients and How These Variables May Affect the Treatment Decisions With Iron

Conditions
-----------------
Chronic Kidney Diseases

Intervention / Treatment
-----------------
* Drug: Serum ferritin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ALL CKD patients stage 3 to 5 not on dialysis Exclusion Criteria: inflammatory chronic diseases IDA Autoimmune disorders Liver diseases Malignancy Infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic kidney disease Patients<br>Chronic kidney Disease Patients stage 3 to stage 5 | Drug: Serum ferritin<br>* Serum ferritin in CKD patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to assess the role of serum ferritin in CKD patients din in CKD patients and how these variability | affect treatment decisions with iron | Recurring |
A Prediction Model for 1-year Mortality After Valvular Heart Surgery

Study Overview
=================
Brief Summary
-----------------
The investigators aimed to develop a predictive model for mortality incorporating nutritional, inflammatory, and perioperative factors in patients undergoing valvular heart surgery. In this retrospective study, the investigators aimed to establish a comprehensive prediction model to predict the risk of 1-year mortality in valvular heart surgery patients through the identification of the inflammatory index most associated with 1-year mortality and developing a prognostic nomogram model incorporating perioperative risk factors with nutritional and inflammatory indices that would be verified by validation cohorts.

Official Title
-----------------
Inflammation-related Markers for the Prediction of Postoperative 1-year Mortality in Patients Undergoing Valvular Heart Surgery

Conditions
-----------------
Patients Undergoing Valvular Heart Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) patients who presented for surgery primarily due to valvular heart disease, including those who required concomitant coronary artery bypass surgery, aortic procedures, or other cardiac procedures. Exclusion Criteria: patients aged <18 years undergoing transcatheter valve replacement, combined congenital heart surgery, or implantation of ventricular assist device, 3) lacking data required for calculating inflammatory indices, or 4) follow-up loss.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1-year mortality after valvular heart surgery | Mortality at follow-up was analysed using time-to-event analysis, with survival time defined as the time from date of surgery until date of death. | 1 year after valvular heart surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neutrophil-to-lymphocyte ratio (NLR), calculated as the number of neutrophils divided by the number of lymphocytes | the white blood cell count with (neutrophil) | within 1 month before surgery | 
| monocyte-to-lymphocyte ratio (MLR), calculated as the number of monocytes divided by the number of lymphocytes | the white blood cell count with ( monocyte) | within 1 month before surgery | 
| platelet-to-lymphocyte ratio (PLR), calculated as the number of platelets divided by the number of lymphocytes | the white blood cell count with platelet | within 1 month before surgery |
Identification and Verification of Candidate Genes Responsible for Optic Disc Drusen Development

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the genetic background for the development of optic disc drusen. The main question is: • Can one or more candidate genes be found? Participants will have a blood sample taken and answer a questionnaire.

Detailed Description
-----------------
The study is an international collaboration between University of Utah, University of Sydney, University of Valladolid, and University of Copenhagen. Patients with Optic disc drusen from 15 known optic disc drusen-families from different countries (USA, Australia, Spain and Denmark) are participating in this study. Blood samples are drawn from each patient and their affected and unaffected family members, and DNA will be extracted. The investigators will do an Optical coherence tomography-scan (according to ODDS Consortium guidelines), and the participant will be asked to fill out the Visual Function Questionnaire (VFQ-25) including four additional questions about optic disc drusen. The etiology of optic disc drusen will be analyzed with a Whole Exome Sequencing (WES), with the use of Next Generation Sequencing (NGS). Prior to WES, all participants will receive genetic counseling by a consultant to ensure awareness of possible secondary genetic findings.

Official Title
-----------------
Identification and Verification of Candidate Genes Responsible for Optic Disc Drusen

Conditions
-----------------
Optic Disk Drusen

Intervention / Treatment
-----------------
* Genetic: Whole exome sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients over the age of 18, who are capable of giving consent Diagnosis of optic disc drusen and a minimum of 3 optic disc drusen-affected family members Exclusion Criteria: Less than 3 affected family members Under the age of 18 or mentally disabled

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Families with optic disc drusen<br> | Genetic: Whole exome sequencing<br>* With Next Generation Sequenzing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Candidate gene | Genetics variants shared by the families will be compared with findings in the remaining families and identical genes will undergo further analysis. | 2023-2024 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optic disc drusen, Genetics
Ultrasound Guided Erector Spinae Plane Block Versus Retrolaminar Plane Block

Study Overview
=================
Brief Summary
-----------------
Retrolaminar block (RLB) and erector spinae plane block (ESPB) are alternative approaches to paravertebral block (PVB) and are advantageous in that they are easier and safer techniques compared with the traditional PVB. These blocks are considered to be compartment blocks or interfascial plane blocks. In these approaches, local anesthetics are assumed to penetrate the superior costotransverse ligament and reach the paravertebral space, although the needle tip is not advanced into the paravertebral space. the study aim to evaluate and compare the analgesic efficacy of retrolaminar plane block and erector spinae plane block.

Official Title
-----------------
Comparison Between the Efficacy of Ultrasound Guided Erector Spinae Plane Block Versus Retrolaminar Plane Block for Postoperative Pain in Patients Undergoing Hepatobiliary Surgery

Conditions
-----------------
Analgesia, Post Operative Pain

Intervention / Treatment
-----------------
* Procedure: retrolaminar block
* Procedure: ESPB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age18-60. Both genders. hepatobiliary surgery. ASA I-III. Exclusion Criteria: Drug allergy. Morbid obesity (BMI >40 kg/m2). Psychiatric disorder. Opiod dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Retrolaminar plane block<br> | Procedure: retrolaminar block<br>* curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina<br>|
| Experimental: ESPB<br> | Procedure: ESPB<br>* curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analogue pain scale | score from 0-10 (0 mean no pain and 10 the worst pain ) | 24 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time of first post operative analgesic request. | time to demand rescue analgesia | 24 hour | 
| Total analgesic consumption | total fentanyl consumption during the first day postoperative | 24 hour |